Jaguar Health grants 11,740 RSUs and options

Jaguar Health, Inc. reported an equity award to officer Jonathan S. Wolin, who serves as Chief of Staff, Chief Compliance Officer and General Counsel.

Rhea-AI Filing Summary

Jaguar Health, Inc. reported an equity award to officer Jonathan S. Wolin, who serves as Chief of Staff, Chief Compliance Officer and General Counsel. On December 11, 2025, he received 11,740 shares of common stock in the form of restricted stock units at a price of $0, granted under the company’s 2014 Stock Incentive Plan. These restricted stock units each represent one share of voting common stock and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date as provided in the grant notice.

On the same date, he was also granted a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, contingent on his continued employment. After these grants, he directly beneficially owned 11,938 shares of common stock and options covering 11,740 shares.

Insider Trade Summary

Grant/Award: 23,480 shares

Grant/Award 2 txns

Insider Wolin Jonathan S.

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	11,740	$0.00	$0.00
Grant/Award	Common Stock	11,740	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 11,740 contracts (Direct); Common Stock — 11,938 shares (Direct)

Footnotes (5)

1. F1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.
2. F2. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
3. F3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
4. F4. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
5. F5. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Jaguar Health (JAGX) report for Jonathan S. Wolin?

The company reported that officer Jonathan S. Wolin received an equity award on December 11, 2025, consisting of restricted stock units in common stock and a stock option grant.

How many Jaguar Health (JAGX) shares were granted to Jonathan S. Wolin?

He was granted 11,740 restricted stock units of common stock at $0 per share and a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share.

When do Jonathan S. Wolin’s restricted stock units in Jaguar Health vest?

Each restricted stock unit represents one share of voting common stock and vests on December 11, 2026, with vested shares delivered on the vesting date as provided in the grant notice.

What are the vesting terms of the Jaguar Health stock options granted to Jonathan S. Wolin?

The 11,740 stock options granted at an exercise price of $1.44 per share will vest ratably on a monthly basis over 12 months from the grant date, so long as he remains employed by Jaguar Health.

What is the expiration date of the stock options granted by Jaguar Health to Jonathan S. Wolin?

The stock options granted to Jonathan S. Wolin expire on December 11, 2035, as stated in the filing.

How many Jaguar Health shares did Jonathan S. Wolin beneficially own after the reported transactions?

Following the transactions, he directly beneficially owned 11,938 shares of Jaguar Health common stock and held 11,740 stock options.

Under which plan were Jonathan S. Wolin’s Jaguar Health equity awards granted?

Both the restricted stock units and stock options were granted pursuant to Jaguar Health’s 2014 Stock Incentive Plan, as approved by the board of directors on December 11, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wolin Jonathan S.

(Last) (First) (Middle)

C/O JAGUAR HEALTH, INC.

200 PINE ST., STE 400

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [ JAGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	12/11/2025(2)(3)		A		11,740	A	$0	11,938(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$1.44	12/11/2025(2)		A		11,740		(5)	12/11/2035	Common Stock	11,740	$0	11,740	D

Explanation of Responses:

1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.

2. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.

4. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.

5. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

Remarks:

Chief of Staff, Chief Compliance Officer & General Counsel

	/s/ Jonathan S. Wolin	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.